Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular Events.

ABSTRACT:

Importance

Belantamab mafodotin (belamaf)-containing regimens are effective treatment options for patients with relapsed and/or refractory multiple myeloma. Ocular events are a common adverse effect of belamaf treatment, which can be managed by physicians, following appropriate training, to minimize their impact on the patient.

Objective

To develop clinical recommendations for the identification, monitoring, and management of ocular events associated with belamaf therapy, and guidance for any required dose modification.

Evidence review

A systematic literature review was conducted and an international group of hematologists and ophthalmologists reviewed clinical trial data, real-world evidence, and published literature on belamaf-associated ocular events. This literatu

SUBMITTER: Terpos E 

PROVIDER: S-EPMC12417747 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature